ABBV Stock Trails Peers Amid Strong Financials

AbbVie's stock performance is puzzling, considering its solid financials. The company delivered revenue growth of 10.4% and a 34% operating margin over the last year, ranking near the top of its peer group.

However, AbbVie's stock return lags behind its peers, with a 30% gain in the past year compared to Merck's +67%. This disconnect suggests that the market may be pricing in future competitive threats.

The company's operational strength is clear, driven by its immunology and neuroscience portfolios. Sales of SKYRIZI and RINVOQ grew 24%, but AbbVie's stock trades at a premium valuation without the corresponding premium performance.

AbbVie's answer to this challenge lies in building new growth platforms, including the recent acquisition of Apogee Therapeutics. The company's Parkinson's portfolio is a key test of its strategy, with peak sales expected to reach over $5 billion. The upcoming U.S. approval and launch of a key drug candidate will be crucial in determining AbbVie's future growth prospects.